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Abstract
Background: Neurofibromatosis type 1 is one of the most common autosomal dominant
disorders, affecting about 1:3,500 individuals. NF1 exon 7 displays weakly defined exon-intron
boundaries, and is particularly prone to missplicing.
Methods: In this study we investigated the expression of exon 7 transcripts using bioinformatic
identification of splicing regulatory sequences, and functional minigene analysis of four sequence
changes [c.910C>T (R304X), c.945G>A/c.946C>A (Q315Q/L316M), c.1005T>C (N335N)]
identified in exon 7 of three different NF1 patients.
Results: Our results detected the presence of three exonic splicing enhancers (ESEs) and one
putative exonic splicing silencer (ESS) element. The wild type minigene assay resulted in three
alternative isoforms, including a transcript lacking NF1 exon 7 (NF1ΔE7). Both the wild type and
the mutated constructs shared NF1ΔE7 in addition to the complete messenger, but displayed a
different ratio between the two transcripts. In the presence of R304X and Q315Q/L316M
mutations, the relative proportion between the different isoforms is shifted toward the expression
of NF1ΔE7, while in the presence of N335N variant, the NF1ΔE7 expression is abolished.
Conclusion: In conclusion, it appears mandatory to investigate the role of each nucleotide change
within the NF1 coding sequence, since a significant proportion of NF1 exon 7 mutations affects pre-
mRNA splicing, by disrupting exonic splicing motifs and modifying the delicate balance between
aberrantly and correctly spliced transcripts.
Background
Alternative splicing, the process by which exons are
included or excluded in the mature mRNA, is an impor-
tant mechanism whereby different transcripts are gener-
ated from the same gene unit. In fact, most human genes
are transcribed in multiple alternative mRNAs, according
to different regulatory programs, resulting in functionally
different protein isoforms [1]. In the best characterized
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post-transcriptional regulation is tissue or developmental
stage specific and may be mediated by intronic and exonic
cis elements. These elements, which are important for the
correct splice-site identification, can act by stimulating
(exonic splicing enhancers, ESEs) or repressing (exonic
splicing silencers, ESSs) the exon's splicing [2].
Neurofibromatosis type 1 (NF1, MIM#162200) is one of
the most common autosomal dominant disorders, affect-
ing about 1:3,500 individuals in all ethnic groups. The
NF1 gene is approximately 280 kb in size and maps to
chromosome 17q11.2 [3-5]. NF1 contains 60 exons, with
an 11- to 13-kb transcript and an open reading frame cod-
ing for 2,818 amino acids [6]. The disease is fully pene-
trant and the diagnosis of NF1 is based on the clinical
criteria recommended by NIH Consensus Conference
(Stumpf, et al., 1988), which include multiple cafè-au-lait
spots, cutaneous or subcutaneous neurofibromas, plexi-
form neurofibromas, axillary or inguinal freckling, optic
gliomas, and iris Lish nodules. Although NF1 mutations
are distributed along the entire coding sequence, no gen-
otype-phenotype correlation has been found so far [7],
with the exception of the recurrent and atypical deletions
underlying NF1 microdeletion syndrome [8].
The NF1 gene is ubiquitously expressed, and four normal
in-frame NF1 splice isoforms are known, brain specific
9br isoform (30 bp) [9], exon 10a-2 isoform (45 bp) [10],
exon 23a isoform (63 bp), which are expressed in all tis-
sues at various levels [11], and the muscle specific exon
48a isoform (54 bp) [12]. In addition, several other alter-
native transcripts have been described, including ex29-,
ex30-, ex29/30- and the N-isoform [13,14].
Mutation analysis has shown that approximately 50% of
NF1 mutations result in splicing alterations [15-18]. In
some cases, splicing mutations do not occur at the con-
served AG/GT dinucleotides of the splice sites. For exam-
ple, mutations leading to stop codons in exon 7 and 37 of
NF1 gene have been reported to be involved in exon skip-
ping [18-21]. In addition, mutational analysis of the NF1
gene disclosed several additional splice variants in which
specific exons are skipped in fresh lymphocytes of unaf-
fected persons, albeit typically at low levels [22,23]. A
number of studies have also reported that some of these
transcripts are more abundant when RNA from aged
blood or from blood kept at non-physiological tempera-
tures is analyzed [15,22,24,25].
The expression of an alternative transcript lacking exon 7
has been demonstrated [17,26]. Indeed, NF1 exon 7 dis-
plays weakly defined exon-intron boundaries, and is par-
ticularly prone to aberrant splicing. In the present study,
we have used in silico and in vitro analysis to evaluate the
functional consequences on gene expression of four
nucleotide variants detected in NF1 exon 7, including a
nonsense mutation (R304X), a missense mutation
(L316M), and two silent changes (Q315Q and N335N).
Since both Q315Q and L316M mutations were together
in cis in the same patients [27], our analysis aim was to
understand their effect together and independently.
Methods
DNA mutation analysis
The nucleotide variants investigated in this study include
a recurrent nonsense mutation [c.910C>T (R304X)]
[22,27-29] and a novel silent change [c.1005T>C
(N335N)] identified using denaturing high performance
liquid chromatography (dHPLC) followed by bidirec-
tional sequencing, as well as a silent change and a mis-
sense mutation occurring together in cis in the same
patient [c.945G>A/c.946C>A (Q315Q/L316M)], and pre-
viously reported by us [27]. PCR conditions, amplicon
length, and resolution temperatures for dHPLC analysis
are reported elsewhere [28,30]. The N335N silent change
was found in a two generation NF1 family (family NF-01)
carrying another NF1 gene mutation, a frameshift dele-
tion (c.476delC) in exon 4a. The silent change N335N
was found in the proband (II-2) and her child (III-1),
both affected by NF1, and in the proband's father (I-1)
presenting out of NF1 clinical signs only three cutaneous
neurofibromas. Frameshift mutation c.476delC was
detected in the proband and her child, but not in the
proband's father. Both N335N and c.476delC were not
found in 200 healthy subjects. Microsatellite analysis per-
formed using 10 markers tightly linked to the NF1 locus
(D17S1873, D17S841, D17S1863, D17S635, D17S1166,
IVS-38, 3'NF1-1, D17S1800, 3'NF1-2, D17S798) showed
that N335N and c.476delC co-segregated on the same
chromosome 17. Pedigree microsatellite analysis details
of family NF-01 are shown in Figure 1. The project was
approved by the institutional review board and all partic-
ipants provided informed consent.
Prediction of exonic splice enhancers
The NF1 exon 7 coding sequence including sequence
changes Q315Q, L316M, R304X and N335N was ana-
lyzed using the online ESEfinder web interface (Release
1.1) [31] which performs searches for putative ESEs in
query sequences using weight matrices corresponding to
the motifs of four different human serine/arginine-residue
proteins (SR proteins): SF2/ASF, SC35, SRp40, and
SRp55. The score for a given sequence was considered to
be potentially significant if greater than the default thresh-
old value defined in the input page. These values were set
as follows: 1.956 for SF2/ASF, 2.383 for SC35, 2.670 for
SRp40, and 2.676 for the SRp55.Page 2 of 9
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Family NF-01, showing pedigree numbers by generation and person number (i.e., I:1 to III:1)igure 1
Family NF-01, showing pedigree numbers by generation and person number (i.e., I:1 to III:1). NF1 affected individuals are 
denoted by a blackened symbol, unaffected by an unblackened symbol. The individual carrying isolated neurofibromas is 
denoted by a partially blackened symbol. The haplotypes from linkage analysis of chromosome 17 are shown. Individuals II:2 
and III:1 carry the N335N silent mutation and the c.476delC deletion, while individual I:1 carries only the N335N variant.
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Minigene constructs were generated and transfected into
cos-1 cells. Exon 7 of the NF1 gene and flanking intronic
sequence were amplified using as template the DNA of a
non-affected individual. Primers NF1-7F (5'-cacacactcga-
gAACAGCTTGTTTGGGAAGGA-3') and NF1-7R (5'-
cacacaggatccGGCCCTAATTGCCACATTATT-3') were used
to generate a fragment containing exon 7 as well as 258 bp
of 5' and 248 bp of 3' of intronic flanking sequence. The
forward primer contains a 5'-XhoI linker, whereas the
reverse primer contains a 5'-BamHI linker. The PCR
amplification reaction was performed on 100 ng genomic
DNA in a standard 50 μL volume, containing 1× Opti-
mase reaction buffer (Transgenomic, Crewe, UK), 1.5 mM
MgSO4, 1 μM of each primer, 0.2 μM dNTPs, and 2.5 U
Optimase TaqDNA polymerase (Transgenomic, Crewe,
UK) in a 9700 thermal cycler (Applied Biosystem, Foster-
City, CA). Thermal conditions were 35 cycles of 95°C for
30 seconds, 57°C for 30 seconds, and 72°C for 1 minute,
preceded by 5 minutes at 95°C and followed by a final
elongation step at 72°C for 10 minutes.
After confirmation of successful amplification through
detection of the expected 680 bp band on the agarose gel,
the products were digested with XhoI (Promega, Madison,
WI, USA) and BamHI (Promega, Madison, WI, USA)
restriction enzymes. The exon trapping expression vector
pSPL3 (Invitrogen Corporation, Carlsbad, CA) contains a
replicon and Apr marker for growth in E. coli, an SV40 seg-
ment for replication and transcription in cos-1 cells, HIV-
1 tat splicing signals, and a multiple cloning site. The tat
segment contains an intron, splice donor (SD) and splice
acceptor (SA) sites, and flanking exon sequences. The
insert was directly ligated between the SD and SA sites into
the XhoI/BamHI restriction points. Ligation into pSPL3
was performed at room temperature for 30 min, using T4
DNA ligase (Invitrogen Corporation, Carlsbad, CA). E.
coli DH5α competent cells (Invitrogen Corporation,
Carlsbad, CA) were transformed with the plasmid con-
structs and plated overnight. The resulting clones were
checked for fragment orientation and sequenced. Mini-
gene constructs were isolated using a midiprep kit (Qia-
gen, Hilden, Germany). The resulting pSPL3-NF1-7-wt
minigene construct is shown in Figure 2. The sequence
changes were independently introduced in the pSPL3-
NF1-7-wt by means of the QuickChange Site-Direct Muta-
genesis Kit (Stratagene, La Jolla, CA), as instructed by the
manufacturer. The changes made in pSPL3-NF1-7-wt are
shown in Figure 2, and Table 1 lists the mutagenic primers
used. All the mutants were sequenced to confirm that only
the desired changes were introduced, and were then iso-
lated with a miniprep kit (Qiagen, Hilden, Germany). The
minigene constructs containing either the wild type
sequence or a exon 7 variant were transfected into cos-1
cells by electroporation.
Approximately 2.5 × 106 cos-1 cells were trypsinized,
washed with cold PBS 1× buffer (Mg2+ and Ca2+ free) and
then resuspended in 800 μl of the same PBS solution. Two
μg of normal or mutant minigene DNAs were added to
the cell suspension in 0.4 cm gap sterile cuvettes. The cell-
DNA mixture was then incubated on ice for 10 min and
electroporated at 4°C using a Bio-Rad Gene Pulser II (Bio-
Rad, Richmond, CA) at a setting of 300 Volts, 250 μF.
Electroporated cells were then incubated on ice for 10
min, diluted 1:20 in complete medium and cultured in T-
75 flasks at 37°C in a humidified atmosphere under 5%
CO2 for at least 48 h. Total cellular RNA from the trans-
fected cos-1 cells was purified by the acid guanidine-phe-
nol-chloroform method and used for RT-PCR to confirm
the splicing patterns. First strand cDNA was synthesized
from 2 to 3 μg of total RNA by random-primed reverse
transcription with Superscript II Reverse Transcriptase
(Invitrogen Corporation, Carlsbad, CA). To evaluate the
pattern of transcripts from the transfected minigenes, the
following vector-specific primers were used for RT-PCR
amplification: a forward primer SD6 (5'-TCTGAGTCAC-
CTGGACAACC-3') and a reverse primer SA2 (5'-ATCT-
CAGTGGTATTTGTGAGC-3'). The PCR amplification
reaction was performed as follows: in 50 μL volume, 2 μl
of cDNA, 5 μl of Expand High Fidelity buffer 3 (Roche,
Mannheim, Germany), 1 μM of each primer, 0.8 μM
dNTPs, and 2.6 U Expand High Fidelity enzyme mix
(Roche, Mannheim, Germany) in a 9700 (Applied Biosys-
tem, FosterCity, CA, USA) thermal cycler. Thermal condi-
tions were 30 cycles of 95°C for 30 seconds, 58°C for 30
seconds, and 68°C for 1 minute, preceded by 2 minutes at
95°C, and followed by a final elongation step at 68°C for
10 minutes. The PCR products were separated by electro-
phoresis on a 3% agarose gel and each band signal was
quantified by Quantity One software (Bio-Rad, Rich-
mond, CA). All transcripts were analyzed by sequencing.
GenBank access
The human NF1 exon\intron 7 sequence was derived
from genomic NF1 sequence [GenBank: NM_000267].
Results
Using bioinformatic identification of putative regulatory
sequences and functional minigene analysis we have eval-
uated the effect on the NF1 pre-mRNA splicing process of
four nucleotide variants detected in NF1 exon 7 of
patients with a clinical diagnosis of NF1. These included a
novel silent change (N335N), and three mutations
(R304X, Q315Q and L316M) previously reported [22,27-
29]. All variants, except R304X, were predicted by ESE-
finder to destroy or create an ESE element. The predictions
for the mutated exonic sequences are summarized in
Table 2. The R304X mutation does not add or abolish any
ESE sequence, while the Q315Q and the L316M changes
abolish respectively a SF2/ASF and a SC35 ESE motif. As aPage 4 of 9
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the SRp40 protein is introduced.
To confirm these predictions, we performed in vitro exper-
iments that tested the splicing enhancement capacity of
the wild type and mutant sequences comprising the pre-
dicted ESEs motifs. Figure 3 shows the amplified PCR
spliced products of the minigene constructs, produced
from primer SD6 and primer SA2 after the transfection.
Each band was quantified by the Quantity One software
(Bio-Rad, Richmond, CA). The wild type construct
showed three splicing products in different proportions: a
fragment of 435 bp (86%), another 403-bp fragment
(2%), and a third of 261 bp (11%). After gel extraction,
each PCR product was directly sequenced. The 435 bp
PCR product included exon 7 and its intronic flanking
sequences, the 403 bp fragment matched with the
expected exon 7, but lacked the last 32 nucleotides, and
the third band of 261 bp corresponded to a transcript
lacking the entire sequence of exon 7 (NF1ΔE7). The con-
struct containing both the Q315Q and the L316M
changes showed only a single PCR product matching with
NF1ΔE7. The constructs containing respectively the
L316M, the Q315Q and the R304X changes disclosed the
same three bands as the wild type, but in different propor-
tions, with the NF1ΔE7 strongly represented, and corre-
sponding respectively to 75%, 86% and 44% of the three
fragments. The L316M, Q315Q and R304X constructs
expressed mRNAs that included the 403-bp exon 7 prod-
uct. The construct containing the N335N change showed
Table 1: Sequence primers used for in vitro mutagenesis.
Mutation Mutagenic primer plus Mutagenic primer minus
R304X 5'-AAGTTATTTCTGGACAGTCTATGAAAAGCTCTTGCTGGCCATGG-3' 5'-CCATGGCCAGCAAGAGCTTTTCATAGACTGTCCAGAAATAACTT-3'
Q315Q 5'-GGCCATGGAGGAAGTAGGCAACTGACAGAAAGTGCTGCAATTG-3' 5'-CAATTGCAGCACTTTCTGTCAGTTGCCTACTTCCTCCATGGCC-3'
L316M 5'-GGCCATGGAGGAAGTAGGCAGATGACAGAAAGTGCTGCAATTG-3' 5'-CAATTGCAGCACTTTCTGTCATCTGCCTACTTCCTCCATGGCC-3'
Q315Q+L316M 5'-GGCCATGGAGGAAGTAGGCAAATGACAGAAAGTGCTGCAATTG-3' 5'-CAATTGCAGCACTTTCTGTCATTTGCCTACTTCCTCCATGGCC-3'
N335N 5'-GTAAAGCAAGTACTTACATCAACTGGGAAGATAACTCTGTC-3' 5'-GACAGAGTTATCTTCCCAGTTGATGTAAGTACTTGCTTTAC-3'
Representation of the pSPL3-NF1-7 minigene constructFigure 2
Representation of the pSPL3-NF1-7 minigene construct. Genomic sequence from exon 7 of the NF1 gene along with 258 bp of 
5' and 248 bp of 3' intronic flanking sequence was ligated into pSPL3 plasmid. Shaded sequences describe the nucleotide 
changes introduced independently by in vitro mutagenesis to obtain the mutated constructs.Page 5 of 9
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and its flanking intronic sequences.
Discussion
In this study four NF1 exon 7 variants detected in three
different patients with NF1 have been investigated using
in silico prediction to determine their effect on ESE
sequences and by in vitro studies to assess their functional
significance on the splicing process. The mutant series
included a recurrent nonsense mutation [c.910C>T
(R304X)] [22,29], a novel silent change [c.1005T>C
(N335N)], and a silent change and a missense mutation
[c.945G>A/c.946C>A (Q315Q/L316M)] occurring
together in cis in the same patient [27]. In silico analysis
showed that the presence of the Q315Q and the L316M
mutations each caused the loss of an ESE motif (SF2/ASF
and SC35 protein respectively), suggesting a role for these
nucleotide sequences in exon 7 retention in the NF1 mes-
sage. Using the minigene assay, we demonstrated that the
presence of the Q315Q and L316M mutations consist-
ently shifted the proportion between the isoforms toward
the expression of NF1ΔE7, enhancing exon 7 skipping and
resulting in decreased levels of full length neurofibromin
in vivo. Whereas the construct containing both Q315Q
and L316M changes showed only the presence of NF1ΔE7
transcript, the constructs containing either the Q315Q or
the L316M alone retained some wild type transcript. As
predicted by ESEfinder software, Q315Q and L316M are
located in two ESE motifs recognized by two different SR
proteins. Each mutation individually affects only one ESE
element and thus allows for the expression of a small
amount of full length transcript. Conversely, the presence
of both changes destroys two ESE elements and com-
pletely inhibits any residual inclusion of exon 7. Accord-
ing to the minigene results, RT-PCR analysis of the patient
carrying the Q315Q and L316M mutations showed the
presence of an additional transcript lacking NF1 exon 7,
which accounts for 61% of the entire message [27]. Based
on the ESEfinder results, the R304X mutation was not
found to substantially affect any ESE element. However,
when this mutation was placed in a heterologous mini-
gene context, it was able to enhance the skipping of exon
7. Similar results were obtained by others expressing the
R304X into a different vector [32]. Using RESCUE-ESE, a
computational method alternative to ESEfinder, the same
authors were able to predict that mutation R304X causes
the loss of a cluster of two hexamer motifs in exon 7, but
concomitantly creates two novel hexamer motifs. They
speculated that the loss of the predicted ESE sites as a
result of R304X has a dominant effect over the increase in
the score of the new ESE sites. The results of another study
suggested that R304X mutation substantially alters the
predicted minimum free-energy structure of exon 7 [18],
although this result has not been confirmed by others
[32].
In our experiment, the search for possible SR protein
binding motifs in NF1 exon 7 using the ESEfinder web
interface [31] showed the presence of three ESE elements
in the wild type sequence. This finding and the knowledge
of the weak exon-intron boundaries of NF1 exon 7
[17,26,27] are consistent with the occurrence of exon 7
alternative splicing also seen in non-pathological condi-
tions. Although exon 7 skipping without sequence altera-
tions is mainly induced by stressful factors such as the
amplification of RNA from aged blood [22,23], a small
amount of NF1ΔE7 isoform (<1%) was also observed
from RNA extracted immediately following blood draw-
ing [17,26]. Consistently, the wild type minigene con-
struct analysis showed the presence of three transcripts,
one including exon 7, one lacking the entire exon 7 and a
third lacking the last 32 nucleotides of exon 7, indicating
the in vitro existence of an equilibrium between splicing
products of the NF1 gene. Regarding the wild type con-
struct, NF1ΔE7 is less expressed than the other transcripts.
R304X in silico analysis did not produce relevant results,
while in vitro analysis shows a reduced expression of full
length transcripts, even if weaker than Q315Q and L316M
mutations. The transcript lacking the last 32 nucleotides
of exon 7 was expressed by all minigene constructs. To our
knowledge, a messanger lacking the last 32 nucleotides of
exon 7 has not been observed previously [17]. Although
this transcript could represent a NF1 isoform expressed at
a very low level, we cannot exclude that this message is an
artefact of the minigene assay. In fact, the proportion of
exon-including and exon lacking spliced minigene tran-
scripts does not always correspond precisely to the levels
measured in patients [32]. It should also be considered
Table 2: ESE Finder results for NF1 exon 7 mutations.
Mutation SRp40(1) Threshold: 2.670 SRp40(2) Threshold: 2.670 SC35 Threshold: 2.383 SF2/ASF Threshold: 1.956
Ex7 WT 3,009308 - 2,855838 2,825583
Ex7 c.910C>T (R304X) 3,366003 ↑ - 2,855838 2,825583
Ex7 c.945G>A (Q315Q) 3,009308 - 3,281102 ↑ Below Thr ↓
Ex7 c.946C>A (L316M) 3,009308 - Below Thr ↓ 3,819131 ↑
Ex7 Q315Q+L316M 3,009308 - Below Thr ↓ Below Thr ↓
Ex7 c.1005T>C (N335N) 3,009308 3,455269 + 2,855838 2,825583
SRp40, SC35 and SF2/ASF are four human SR proteins linked to ESE sequences. ↑ indicates an increased score compared to the threshold value. ↓ 
indicates a score below the threshold value. + indicates the gain of a SR protein binding site.Page 6 of 9
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result in an out-of-frame transcript, possibly degraded by
nonsense-mediated mRNA decay pathway.
Whereas Q315Q, L316M and R304X mutations shift the
equilibrium between NF1 transcripts towards the skip-
ping of exon 7, minigene analysis of the N335N silent
change demonstrated that this variant completely shifts
the equilibrium between the NF1 messengers towards the
full length transcript, being the only detectable transcript.
It was previously reported that the sequence around
nucleotide 1007G had a weak ESE activity and a mutation
at this site caused only a mild splicing defect [32]. It was
speculated that this ESE sequence was part of a composite
exonic regulatory element of splicing (CERES), defined as
an exonic regulatory splicing element, having overlapping
enhancer and silencer functions [33]. Using ESEfinder
analysis we were able to predict that the consequence of
the N335N change is the introduction of a novel ESE
motif for the SRp40 protein. However, ExonScan [34,35],
another algorithm which simulates splicing based on
known or putative splicing-related motifs, gives a different
prediction showing that the mutation (c.910T>C) N335N
results in the loss of an ESS (ATCAAT) motif in exon 7, but
concurrently creates another novel ESS motif (AACTGG)
(data not shown). As previously hypothesized for the
R304X mutation and also for the N335N silent change,
the loss of a putative splicing-related motif has a domi-
a. Post transfection PCR products of the minigene constructs obtained by SD6 and SA2 primersFigure 3
a. Post transfection PCR products of the minigene constructs obtained by SD6 and SA2 primers. The upper band indicates a 
435 bp product encompassing exon 7. The lower band indicates a 261 bp product with exon 7 skipping. The central band cor-
responds to an alternative product of 403 bp. b. Quantification by Quantity One software of the bands showed on the top. The 
intensity of each band, representing the amount of each transcript, is expressed as percentage.Page 7 of 9
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motif. Accordingly, in vitro analysis has proven that nucle-
otide 1005T could partially belong to an ESS, since a
change destroying this sequence completely eliminates
NF1ΔE7 expression. The presence of some ESE/ESS ele-
ments in NF1 exon 7 and the existence of NF1ΔE7 in
healthy individuals suggest that the splicing of exon 7 is
subject to fine regulation. Notably, NF1 exon 7 is in-
frame, thus the resulting protein could theoretically retain
some function, missing only the residues encoded by this
exon. As reported in our previous studies even if NF1 exon
7 does not belong to the neurofibromin active site it is a
mutation hot spot, suggesting that exon 7 is important for
the pathogenesis of NF1 [27,30,36]. It could be specu-
lated that the NF1ΔE7 isoform could have a specific role
in cellular metabolism, or that its' expression could repre-
sent a mechanism to regulate intracellular neurofibromin
levels. However, the N335N change, which eliminates the
in vitro expression of NF1ΔE7, was detected in a subject
who, before clinical evaluation of full blown NF1 in his
daughter and grandson, did not fit with the NF1 diagnos-
tic criteria, manifesting only three cutaneous neurofibro-
mas. This incomplete NF1 phenotype could be explained
by the presence of undetectable mosaicism for the
c.476delC mutation which was absent in the germline
DNA of this subject, but was found in cis with the inher-
ited N335N change in the germline DNA of his daughter
and grandson. Unfortunately, none of the neurofibromas
could be verified by biopsy to prove this hypothesis. Alter-
natively, it could be possible that c.476delC frameshift
mutation could have arisen de novo on the same allele of
N335N during spermatogenesis. However, the contribu-
tion of the N335N variant to the NF1 clinical phenotype
is difficult to infer. In fact, it is difficult to imagine for this
silent substitution to have the same effect on exon 7 skip-
ping regardless of the upstream c.476delC frameshift
mutation, as this type of mutations are expected to trigger
NMD of the corresponding allele. However, lack of this
change in normal individuals appears to rule out its poly-
morphic nature. Conversely, a pathogenic role for the
Q315Q and L316M is easier to infer, as they are de novo
mutations belonging to contiguous codons [27]. Moreo-
ver, as shown by the minigene analysis, the presence of
each mutation individually is sufficient to enhance the
expression of NF1ΔE7, thus suggesting that each of these
mutations per se can result in NF1. In the present case they
acted additively to cause the NF1 patient phenotype.
Conclusion
In the present study we observed that a significant propor-
tion of neurofibromatosis associated mutations (mis-
sense, nonsense or silent changes) residing in NF1 exon 7
affect pre-mRNA splicing by disrupting exonic splicing
motifs, shifting the transcripts balance towards aberrantly
spliced transcripts and producing two types of transcripts:
those with the original mutation, and those with the skip-
ping [27]. Therefore, it should be mandatory to investi-
gate each nucleotide change occurring within the NF1
coding sequence for their potential pathogenetic role in
NF1.
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